What Is ABT Fair Value?
Abbott Laboratories (ABT) fair value estimate using multiple valuation models, updated daily.
As of September 15, 2026, Abbott Laboratories (ABT) has a composite fair value estimate of $86.93 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $102.03, suggesting the stock is fair value by 14.8%.
Data as of September 15, 2026 (today)
Composite Fair Value
Fair Value4 of 4 models$86.93
vs. current price of $102.03(-14.8%)
How Is ABT Fair Value Calculated?
Four independent models estimate what ABT is worth. Each uses different inputs and assumptions. The composite blends them by weight.
ABT Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$113.12
+10.9%Fair Value
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$76.04
-25.5%Overvalued
Inputs used
ABT Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$60.57
-40.6%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$55.20
-45.9%Overvalued
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $102.03 is 10.9% below this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $7.82B | $7.30B |
| Year 2 | $8.49B | $7.40B |
| Year 3 | $9.22B | $7.50B |
| Year 4 | $10.00B | $7.59B |
| Year 5 | $10.86B | $7.69B |
| Year 6 | $11.78B | $7.79B |
| Year 7 | $12.79B | $7.89B |
| Year 8 | $13.88B | $8.00B |
| Year 9 | $15.07B | $8.10B |
| Year 10 | $16.35B | $8.21B |
| Terminal Value | $361.52B | $181.45B |
What Are ABT's Key Financial Metrics?
Earnings & Growth
Current Price
$102.03
EPS (TTM)
$3.09
Forward P/E
16.8
Profit Margin
11.6%
Cash & Balance Sheet
Free Cash Flow
7.2B
EBITDA
11.7B
Book Value
$29.54
Total Debt
32.7B
What Do Analysts Say About ABT?
Low
$103.00
Average
$120.26
High
$135.00
Upside
+17.9%
ABT Fair Value FAQ
What is the fair value of ABT?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), ABT's estimated fair value is $86.93. The stock is currently trading at $102.03, which makes it fair value by our analysis.
How is ABT's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is ABT overvalued or undervalued?
Based on our analysis, ABT is fair value. The current price of $102.03 is 14.8% above our estimated fair value of $86.93.
What do Wall Street analysts say about ABT?
25 analysts cover Abbott Laboratories with a consensus rating of "Buy." The average price target is $120.26, ranging from $103.00 to $135.00. This implies 17.9% upside from the current price.